Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 70.58% is in line with its 5-year average of 66.23%, near the high end of its 5-year range (60.94%–73.50%).
1.27% above its 12-month average of 69.69%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 73.50%.
GROSS MARGIN
70.58%
GROSS MARGIN AVG TTM
69.69%
GROSS MARGIN AVG 3Y
66.95%
GROSS MARGIN AVG 5Y
66.23%
GROSS MARGIN AVG 10Y
63.93%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.27%
CURRENT VS 3Y AVG
+5.42%
CURRENT VS 5Y AVG
+6.57%
CURRENT VS 10Y AVG
+10.40%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
47.19%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
+49.58%
vs the sector median at left
Market Cap
$3.62B
Gross Margin
-43.89%
TTM Avg
0.67%
3Y Avg
45.02%
5Y Avg
61.14%
Market Cap
$3.58B
Gross Margin
71.45%
TTM Avg
69.72%
3Y Avg
68.83%
5Y Avg
69.16%
Market Cap
$3.45B
Gross Margin
91.13%
TTM Avg
91.57%
3Y Avg
93.72%
5Y Avg
94.38%
Market Cap
$3.24B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.16B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
50.00%
5Y Avg
66.67%
Market Cap
$3.15B
Gross Margin
91.14%
TTM Avg
90.25%
3Y Avg
87.92%
5Y Avg
58.61%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CareDx, Inc (CDNA) | $3.68B | 70.58% | 69.69% | 66.95% | 66.23% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.62B | -43.89% | 0.67% | 45.02% | 61.14% |
| Celcuity Inc. (CELC)vs › | $3.62B | 0.00% | 0.00% | 0.00% | 0.00% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.58B | 71.45% | 69.72% | 68.83% | 69.16% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.45B | 91.13% | 91.57% | 93.72% | 94.38% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.24B | 0.00% | 0.00% | 0.00% | 0.00% |
| ICU Medical, Inc. (ICUI)vs › | $4.03B | 37.56% | 35.69% | 33.68% | 34.73% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | 0.00% | 0.00% | 50.00% | 66.67% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | 91.14% | 90.25% | 87.92% | 58.61% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.18B | 0.00% | 25.88% | 57.90% | -575.35% |
Gross Margin
70.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 73.50% |
| 2026-03-31 | 71.43% |
| 2025-12-31 | 67.24% |
| 2025-09-30 | 69.36% |
| 2025-06-30 | 66.94% |
| 2025-03-31 | 66.45% |
| 2024-12-31 | 67.45% |
| 2024-09-30 | 66.73% |
| 2024-06-30 | 69.66% |
| 2024-03-31 | 64.01% |
| 2023-12-31 | 60.94% |
| 2023-09-30 | 63.49% |
| 2023-06-30 | 63.18% |
| 2023-03-31 | 66.39% |
| 2022-12-31 | 64.20% |
| 2022-09-30 | 64.34% |
| 2022-06-30 | 65.85% |
| 2022-03-31 | 66.15% |
| 2021-12-31 | 65.92% |
| 2021-09-30 | 67.14% |
| 2021-06-30 | 67.69% |
| 2021-03-31 | 67.98% |
| 2020-12-31 | 67.80% |
| 2020-09-30 | 68.49% |
| 2020-06-30 | 64.06% |
| 2020-03-31 | 67.71% |
| 2019-12-31 | 64.50% |
| 2019-09-30 | 66.01% |
| 2019-06-30 | 63.40% |
| 2019-03-31 | 62.54% |
| 2018-12-31 | 55.30% |
| 2018-09-30 | 58.05% |
| 2018-06-30 | 59.56% |
| 2018-03-31 | 54.57% |
| 2017-12-31 | 55.30% |
| 2017-09-30 | 57.27% |
| 2017-06-30 | 56.92% |
| 2017-03-31 | 53.52% |
| 2016-12-31 | 40.30% |
| 2016-09-30 | 52.23% |
| 2016-06-30 | 45.38% |
| 2016-03-31 | 57.76% |
| 2015-12-31 | 62.61% |
| 2015-09-30 | 64.09% |
| 2015-06-30 | 64.82% |
| 2015-03-31 | 62.43% |
| 2014-12-31 | 72.28% |
| 2014-09-30 | 73.37% |
| 2014-06-30 | 64.54% |
| 2014-03-31 | 63.50% |
| 2013-12-31 | 60.15% |
| 2013-09-30 | 56.90% |
| 2013-06-30 | 61.17% |
| 2013-03-31 | 57.36% |
